SONTD Sontra Medical (MM)

FRANKLIN, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Sontra Medical Corporation (NASDAQ:SONTD) announced today that, following its recently completed reverse stock split, it has regained compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement for continued listing. On August 11, 2006, Sontra completed a 1-for-10 reverse split of its Common Stock and since such date the Company's Common Stock has traded under the current symbol "SONTD". Effective at the opening of business on Monday, September 11, 2006, the Company's Common Stock is expected to trade once again under the symbol "SONT". About Sontra Medical Corporation (http://www.sontra.com/) Sontra Medical Corporation is a technology leader in transdermal science and is developing a non-invasive, continuous transdermal glucose monitor ("CTGM") for principal use in the Intensive Care Market. Through its platform technology, the SonoPrep(R) Permeation System, combined with technical competencies in transdermal drug formulation, analysis, delivery systems and biosensors, the Company is creating a new paradigm in transdermal drug delivery and diagnosis. The CTGM and other company products are being developed for several billion dollar market opportunities, all utilizing skin permeation, chemistry and biosensor technology developed by the Company. In addition, the Company is developing products for transdermal delivery of large molecule drugs and vaccines. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology, including a continuous transdermal glucose monitor for the hospital ICU market; the expected size of the market for the continuous transdermal glucose monitor for the hospital ICU market; the expected benefits and efficacy of the SonoPrep device in connection with diagnostics, vaccine delivery, glucose monitoring and transdermal science; the availability of substantial additional funding to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2005, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us. SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners. Investor Relations Contact: Harry G. Mitchell, CFO 508-530-0311 DATASOURCE: Sontra Medical Corporation CONTACT: Harry G. Mitchell, CFO of Sontra Medical Corporation, +1-508-530-0311, Web site: http://www.sontra.com/

Copyright